The book of records of Ukraine has declared Corvalol medicine made by PJSC Farmak (Kyiv) the most famous sedative on the country’s market. Head of the supervisory board of the company Filia Zhebrovska said at the award ceremony said that Corvalol, developed in 1959 by scientists of Lomonosov Kyiv Chemical and Pharmaceutical Plant, and Farmak has been a legal successor of it since 1991, is being produced at Farmak in line with all European standards.
She said that Farmak produces Corvalol in a closed cycle from the synthesis of a substance to the production of finished dosage forms and guarantees its quality at every stage of production.
In turn, Executive Director Volodymyr Kostiuk said that with the development of pharmaceutical manufacturing technology, Farmak will also improve the production technology of Corvalol and expand the line of ready-made forms of the drug. In particular, at present the drug is marketed in the form of drops, tablets and soft capsules.
“By our example, we will show that modern pharmaceutical production exists in Ukraine. Even the old Soviet Corvalol today is not the same as it was 60 years ago. Now it is produced using modern equipment, manufactured according to all standards of Ukraine, Europe and the United States. Unfortunately, I cannot say this about our rivals, who do not care about quality but occupy the market. I hope the situation will improve in the near future,” he said.
Currently, Farmak has a number of drugs, the production of which in a closed cycle was started by the Lomonosov Kyiv Chemical and Pharmaceutical Plant, in particular, Diazolin, Corvalol, Naphthyzin and Validol.
In general, the company has more than 220 product dossiers, produces about 20 new drugs annually.
The decision to develop technology and create a cardiovascular medicine, similar to Valocordin, which was produced in Germany, at the Lomonosov Kyiv Chemical and Pharmaceutical Plant was made in 1959. The first batch of the drug was released as early as next year at the same enterprise. At that time, it was a know-how – a generic European sedative drug.
Farmak since 1991 is the only manufacturer of Corvalol on the post-Soviet territory. The Corvalol trademark is protected in 15 countries of Europe and Middle Asia, including Germany, Armenia, Georgia, Azerbaijan, Tajikistan, Kyrgyzstan and Kazakhstan.
The Supreme Court has sent a case opened vis-à-vis the well-known medicine brand Corvalol Corvalolum to the Grand Chamber of the Supreme Court. This decision was taken by the court on Tuesday, Head of the Legal Department of PJSC Farmak, lawyer Dmytro Taranchuk has told Interfax-Ukraine.
Having taken this decision, the Supreme Court granted the request of a third party – PJSC Farmak – on sending the case to the Grand Chamber of the Supreme Court.
“This is a lawful decision and was taken in line with all procedural requirements; it will provide an impartial and objective consideration of the case,” the lawyer said.
As reported, the appeal chamber of Ukraine’s Economic Development and Trade Ministry on June 20, 2017, declared the Corvalol Corvalolum trademark used by PJSC Farmak as a well-known one.
Kyiv-based Darnitsa pharmaceutical firm in turn seeks the legal right to produce its own medicine, Corvalol. The firm appealed to the business court of Kyiv seeking to declare the decision of the ministry unlawful. The court of lower instance dismissed Darnitsa’s lawsuit, while Kyiv’s business court of appeals upheld the firm’s counterclaim.
Farmak declares that the name “Corvalol,” which has been produced since 1960, belongs to the company, as the medication was created in 1960 by Lomonosov Kyiv Chemical-Pharmaceutical Plant, and Farmak is the legal successor of the plant.
Since 1991, PJSC Farmak has been the only manufacturer of this medication in the post-Soviet space. The trademark Corvalol is protected in 15 countries of Europe and Central Asia: Germany, Poland, Lithuania, Latvia, Belarus, Moldova, Romania, Bulgaria, Turkmenistan, Armenia, Georgia, Azerbaijan, Tajikistan, Kyrgyzstan, and Kazakhstan.
Darnitsa pharmaceutical firm is one of the ten largest pharmaceutical producers in Ukraine and belongs to the top ten hospital suppliers. The ultimate beneficiary is Hlib Zahoriy.
PJSC Farmak is among Ukraine’s top three pharmaceutical producers and is a member of the Association Manufacturers of Medications of Ukraine (AMMU). PJSC Farmak’s beneficiary is Chairperson of PJSC Farmak’s supervisory board Filia Zhebrovska.
BRAND, CORVALOL, GRAND CHAMBER, MEDICINE, UKRAINIAN SUPREME COURT
